M. Kansara, M. W. Teng, M. J. Smyth, and D. M. Thomas, Translational biology of osteosarcoma, Nat Rev Cancer, vol.14, pp.722-735, 2014.

E. E. Group, Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.25, pp.113-123, 2014.

S. Ferrari and E. Palmerini, Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma, Curr Opin Oncol, vol.19, pp.341-346, 2007.

P. Coyle, J. C. Philcox, L. C. Carey, and A. M. Rofe, Metallothionein: the multipurpose protein, Cell Mol Life Sci, vol.59, pp.627-647, 2002.

A. K. Baltaci, K. Yuce, and R. Mogulkoc, Zinc Metabolism and Metallothioneins, Biol Trace Elem Res, vol.183, pp.22-31, 2018.

M. Si and J. Lang, The roles of metallothioneins in carcinogenesis, J Hematol Oncol, vol.11, 2018.

N. Habel, Zinc chelation: a metallothionein 2A's mechanism of action involved in osteosarcoma cell death and chemotherapy resistance, Cell Death Dis, vol.4, 2013.

W. Yang, Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells, Nucleic Acids Res, vol.41, pp.955-961, 2013.

M. E. Marques-da-costa, In-Vitro and In-Vivo Establishment and Characterization of Bioluminescent Orthotopic Chemotherapy-Resistant Human Osteosarcoma Models in NSG Mice, Cancers (Basel), vol.11, 2019.

L. Deley and M. C. , SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients, Eur J Cancer, vol.43, pp.752-761, 2007.

L. Gatti and F. Zunino, Overview of tumor cell chemoresistance mechanisms, Methods Mol Med, vol.111, pp.127-148, 2005.

Y. H. Lee, DHFR and MDR1 upregulation is associated with chemoresistance in osteosarcoma stem-like cells, Oncol Lett, vol.14, pp.171-179, 2017.

N. Baldini, Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome, N Engl J Med, vol.333, pp.1380-1385, 1995.

H. S. Chan, T. M. Grogan, G. Haddad, G. Deboer, and V. Ling, P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy, J Natl Cancer Inst, vol.89, pp.1706-1715, 1997.

M. Serra, Analysis of P-glycoprotein expression in osteosarcoma, Eur J Cancer, vol.31, 1995.

K. Trieb and R. Kotz, Proteins expressed in osteosarcoma and serum levels as prognostic factors, Int J Biochem Cell Biol, vol.33, pp.11-17, 2001.

H. Uozaki, Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis, Cancer, vol.79, pp.2336-2344, 1997.

T. Ishikawa, The ATP-dependent glutathione S-conjugate export pump, Trends Biochem Sci, vol.17, pp.463-468, 1992.

M. Pljesa-ercegovac, Glutathione Transferases: Potential Targets to Overcome Chemoresistance in Solid Tumors, Int J Mol Sci, vol.19, 2018.

C. Salinas-souza, A. S. Petrilli, and S. R. De-toledo, Glutathione S-transferase polymorphisms in osteosarcoma patients, Pharmacogenet Genomics, vol.20, pp.507-515, 2010.

D. R. Mans, Reactions of glutathione with the catechol, the ortho-quinone and the semi-quinone free radical of etoposide. Consequences for DNA inactivation, Biochem Pharmacol, vol.43, pp.1761-1768, 1992.

A. Lorico, Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione, Cancer Res, vol.57, pp.5238-5242, 1997.

N. Rochet, Establishment, characterisation and partial cytokine expression profile of a new human osteosarcoma cell line (CAL 72), Int J Cancer, vol.82, pp.282-285, 1999.

B. Fournier and P. Price, Characterization of a new human osteosarcoma cell line OHS-4, J Cell Biol, vol.114, pp.577-583, 1991.

D. G. Fuhrich, B. A. Lessey, and R. F. Savaris, Comparison of HSCORE assessment of endometrial beta3 integrin subunit expression with digital HSCORE using computerized image analysis (ImageJ), Anal Quant Cytopathol Histpathol, vol.35, pp.210-216, 2013.